Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) is now up nearly 5%, and Tumai Robotic Remote Surgery has broken through, and the total number of overseas orders in hand has reached 10 units

The Zhitong Finance App learned that minimally invasive robot-B (02252) is now up nearly 5%. As of press release, it has risen 4.74% to HK$9.52, with a turnover of HK$36.822 million.

According to the news, on November 16, at the Minimally Invasive Robotics Group Surgical Robotics Global Remote Command Center in Zhangjiang, Shanghai, French surgeon Dr. Youness Ahallal successfully performed robotic remote prostate cancer treatment surgery using a Chinese-made Tumai robot in Shanghai for patients in Casablanca, Morocco 12,000 kilometers away. The entire operation took less than two hours, and the entire operation was completed remotely. The delay time was only over 100 ms.

Southwest Securities pointed out that as of the first half of '24, the endoscopic robot “Tumai” developed by the company had been commercially installed in 20 domestic hospitals, helping to complete more than 1,300 clinical surgeries on humans, ranking first among domestically produced endoscopic robots. On the overseas side, Tumai's overseas orders have reached a total of 10 units, and 2 have already been commercially installed. This is a landmark milestone in domestic endoscopic surgery robots going overseas. As of the first half of '24, the orthopedic surgery robot Honghu has received a total of about 30 overseas sales orders, and the total number of TKA surgeries worldwide has exceeded 1,300, covering about 70 hospitals.